Global Drugs for Vulvovaginal Candidiasis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Vulvovaginal Candidiasis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
Drugs for Vulvovaginal Candidiasis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Vulvovaginal Candidiasis market is projected to reach US$ 907.4 million in 2034, increasing from US$ 816.6 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2034. Demand from Hospital & Clinic and Pharmacy are the major drivers for the industry.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Vulvovaginal Candidiasis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Hospital & Clinic
Pharmacy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Drugs for Vulvovaginal Candidiasis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Vulvovaginal Candidiasis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Vulvovaginal Candidiasis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Vulvovaginal Candidiasis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Vulvovaginal Candidiasis introduction, etc. Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Drugs for Vulvovaginal Candidiasis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
Drugs for Vulvovaginal Candidiasis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Vulvovaginal Candidiasis market is projected to reach US$ 907.4 million in 2034, increasing from US$ 816.6 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2034. Demand from Hospital & Clinic and Pharmacy are the major drivers for the industry.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Vulvovaginal Candidiasis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Drugs for Vulvovaginal Candidiasis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Vulvovaginal Candidiasis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Vulvovaginal Candidiasis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Vulvovaginal Candidiasis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Vulvovaginal Candidiasis introduction, etc. Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Drugs for Vulvovaginal Candidiasis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices